# Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

> **NCT01931566** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 3494 (actual)

## Conditions studied

- Mild Cognitive Impairment Due to Alzheimer's Disease

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Pioglitazone placebo

## Key facts

- **NCT ID:** NCT01931566
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-01
- **Primary completion:** 2018-07-24
- **Final completion:** 2018-09-06
- **Target enrollment:** 3494 (ACTUAL)
- **Why stopped:** Lack of efficacy of the drug; no safety concern
- **Last updated:** 2019-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01931566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01931566, "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01931566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*